Allarity Therapeutics
ALLR
2 hedge funds and large institutions have $11.7K invested in Allarity Therapeutics in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
33% less funds holding
Funds holding: 3 → 2 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
63% less capital invested
Capital invested by funds: $31.8K → $11.7K (-$20.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$13.8K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$251 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$20.7K |
| 2 |
VF
Virtu Financial
New York
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $9.94K | +$13.8K | +55 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $1.72K | +$251 | +1 | +11% |
|
3
Wells Fargo
San Francisco,
California
| $11 | – | – | – |
|
4
Morgan Stanley
New York
| $2 | – | – | – |
|
|
TSS
5
Two Sigma Securities
New York
| – | -$20.7K | -63 | Closed |
|
|
VF
6
Virtu Financial
New York
| – | -$8K | -25 | Closed |
|
ALLR Hedge Fund Activity: Q1 2024 in Review
2 of the 6,947 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q1 2024, worth a combined $11.7K — down 63% from $31.8K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ALLR and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, opening a new position worth an estimated $13.8K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $20.7K sold.
- 2 institutional investors held Allarity Therapeutics (ALLR) as of Q1 2024, down from 3 in Q4 2023.
- Funds reported $11.7K of Allarity Therapeutics stock for Q1 2024, down 63% quarter-over-quarter.
- 1 fund opened new Allarity Therapeutics positions in Q1 2024 and 2 closed out, a net change of -1 holder.
- The largest Allarity Therapeutics buyer in Q1 2024 was UBS Group, an estimated $13.8K added.
- The largest Allarity Therapeutics seller in Q1 2024 was Two Sigma Securities, an estimated $20.7K sold.
Based on aggregated 13F filings for Q1 2024.